Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions

Prostatic Neoplasms

Interventions

DRUG

QLH12016

oral AR PROTAC

DRUG

abiraterone acetate

oral CYP17 inhibitor

DRUG

enzalutamide

oral androgen receptor inhibitor

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT07104110 - Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter